DNTH vs MRK
Dianthus Therapeutics, Inc. vs Merck & Co. — AI-powered side-by-side comparison
DNTH
Dianthus Therapeutics, Inc.
54
Watch
VS
| Metric | DNTH | MRK |
|---|
| AI Score |
54
|
70
|
| Price |
$108.40
|
$130.34
|
| P/E Ratio |
-834.54×
|
103.53×
|
| ROE |
-32.9%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.0%
|
75.4%
|
| Debt / Equity |
0.00×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
52.5
|
64.5
|
| Beta |
0.082
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for DNTH versus MRK.
MRK leads by 16 points.
MRK scores 70/100 (Buy) versus DNTH at 54/100 (Watch).
DNTH Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -60.8% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- ROE of only -22.5% -- cheap may mean cheap for a reason — Value
- Revenue declining -60.8% YoY -- this is not a growth story right now — Growth
- MACD histogram negative -- bearish momentum — Technical
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical